Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) Products under Development by Stage of Development | 8 | 1 |
| Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) Products under Development by Therapy Area | 9 | 1 |
| Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) Products under Development by Indication | 10 | 1 |
| Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) Pipeline Products Glance | 11 | 1 |
| Early Stage Products | 11 | 1 |
| Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) Products under Development by Companies | 12 | 2 |
| Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) Products under Development by Universities/Institutes | 14 | 2 |
| Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) Therapeutics Assessment | 16 | 5 |
| Assessment by Monotherapy/Combination Products | 16 | 1 |
| Assessment by Mechanism of Action | 17 | 1 |
| Assessment by Route of Administration | 18 | 1 |
| Assessment by Molecule Type | 19 | 2 |
| Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) Companies Involved in Therapeutics Development | 21 | 8 |
| Alchemia Limited | 21 | 1 |
| AstraZeneca Plc | 22 | 1 |
| Carmot Therapeutics Inc | 23 | 1 |
| Diabetica Limited | 24 | 1 |
| Eli Lilly and Company | 25 | 1 |
| Longevity Biotech, Inc | 26 | 1 |
| Sanofi | 27 | 1 |
| Zealand Pharma A/S | 28 | 1 |
| Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) Drug Profiles | 29 | 13 |
| AC-163794 Drug Profile | 29 | 1 |
| DAJC-1 Drug Profile | 30 | 1 |
| LBT-6030 Drug Profile | 31 | 1 |
| SAR-438335 Drug Profile | 32 | 1 |
| Small Molecule to Agonize Gastric Inhibitory Polypeptide for Type 2 Diabetes Drug Profile | 33 | 1 |
| Small Molecules to Agonize GLP-1 and GIP Receptors for Type 2 Diabetes and Obesity Drug Profile | 34 | 1 |
| Synthetic Peptide 1 for Type 2 Diabetes and Obesity Drug Profile | 35 | 1 |
| Synthetic Peptide 1 to Agonize GIPR for Alzheimer's Disease Drug Profile | 36 | 1 |
| Synthetic Peptide to Agonize GIPR for Alzheimer's Disease Drug Profile | 37 | 1 |
| Synthetic Peptide to Agonize GLP-1 Receptor and GIP Receptor for Diabetes Drug Profile | 38 | 1 |
| Synthetic Peptides to Agonize GLP-1, GIP and Glucagon Receptors for Diabetes and Obesity Drug Profile | 39 | 1 |
| ZPDI-70 Drug Profile | 40 | 1 |
| ZPI-98 Drug Profile | 41 | 1 |
| Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) Dormant Projects | 42 | 1 |
| Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) Discontinued Products | 43 | 1 |
| Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) Featured News &Press Releases | 44 | 2 |
| Sep 15, 2015: Zealand presents new preclinical data on its novel GIP peptide therapeutic, ZP-I-98, at the 51st EASD Annual Meeting | 44 | 1 |
| Jun 06, 2015: Presentations on ZP-DI-70, novel Zealand preclinical peptide therapeutics as a possible approach for the treatment of Type 2 diabetes and obesity at the American Diabetes Association s (ADA) 74th Scientific Sessions | 44 | 2 |
| Appendix | 46 | 2 |
| Methodology | 46 | 1 |
| Coverage | 46 | 1 |
| Secondary Research | 46 | 1 |
| Primary Research | 46 | 1 |
| Expert Panel Validation | 46 | 1 |
| Contact Us | 46 | 1 |
| Disclaimer | 47 | 1 |